Trial Profile
A prospective study investigating association of pharmacokinetics and pharmacogenomics with efficacy and safety of gefitinib in subjects advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 30 Nov 2016 New trial record